[Federal Register Volume 60, Number 129 (Thursday, July 6, 1995)]
[Notices]
[Page 35225]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-16621]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 14, 1995, Celgene 
Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, made 
written request to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the Schedule II controlled 
substance Amphetamine (1100).
    The firm plans to manufacture Amphetamine for distribution of the 
bulk active substance to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the above application and may also file a written 
request for a hearing thereon in accordance with 21 CFR 1301.54 and in 
the form prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, United States Department of 
Justice, Washington, DC, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than August 7, 1995.

    Dated: June 29, 1995.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 95-16621 Filed 7-5-95; 8:45 am]
BILLING CODE 4410-09-M